Porphyria refers to a group of rare inherited metabolic disorders caused by enzymatic deficiencies in the heme biosynthesis pathway.These deficiencies lead to the pathological accumulation of neurotoxic porphyrin prec...Porphyria refers to a group of rare inherited metabolic disorders caused by enzymatic deficiencies in the heme biosynthesis pathway.These deficiencies lead to the pathological accumulation of neurotoxic porphyrin precursors,resulting in multisystem damage.Currently,there are no curative therapeutic interventions,and patients frequently experience severe morbidity or life-threatening complic-ations.Among the most critical manifestations is protoporphyric liver disease,in which hepatotoxic porphyrins and their precursors drive progressive hepatic injury and cholestasis.Persistent elevation of these metabolites can lead to irreversible parenchymal damage,significantly affecting both quality of life and long-term prognosis.The clinical presentation of porphyria-associated liver injury is highly variable and often has an insidious onset.However,a subset of patients may experience rapid progression to acute liver failure or fulminant hepatic dysfunction.Diagnosis is based on clinical evaluation and is confirmed by genetic testing.Current treatment strategies are focused on symptom management while underlying disease mechanisms remain unaddressed,posing significant the-rapeutic challenges.This review summarizes the pathophysiology,clinical mani-festations,and diagnostic approaches for porphyria-associated liver injury,highlighting emerging therapies with the potential to improve patient outcomes.展开更多
文摘Porphyria refers to a group of rare inherited metabolic disorders caused by enzymatic deficiencies in the heme biosynthesis pathway.These deficiencies lead to the pathological accumulation of neurotoxic porphyrin precursors,resulting in multisystem damage.Currently,there are no curative therapeutic interventions,and patients frequently experience severe morbidity or life-threatening complic-ations.Among the most critical manifestations is protoporphyric liver disease,in which hepatotoxic porphyrins and their precursors drive progressive hepatic injury and cholestasis.Persistent elevation of these metabolites can lead to irreversible parenchymal damage,significantly affecting both quality of life and long-term prognosis.The clinical presentation of porphyria-associated liver injury is highly variable and often has an insidious onset.However,a subset of patients may experience rapid progression to acute liver failure or fulminant hepatic dysfunction.Diagnosis is based on clinical evaluation and is confirmed by genetic testing.Current treatment strategies are focused on symptom management while underlying disease mechanisms remain unaddressed,posing significant the-rapeutic challenges.This review summarizes the pathophysiology,clinical mani-festations,and diagnostic approaches for porphyria-associated liver injury,highlighting emerging therapies with the potential to improve patient outcomes.
